Skip to content
DataLookout
Menu

BAFANCT07935811

An Open-label, Non-randomised Safety and Tolerability Proof of Concept Trial to Examine Multiple Dosing Addition of Glycocholate (GC) and Butyrate (B) to Increase Calcium Absorption in Healthy Participants That Have Undergone Roux-en-Y Gastric Bypass (BAFA)

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Timeframe: From the first administration of BAFA (Visit 2) through the post-treatment follow-up visit (Visit 5, approximately 5-6 weeks after treatment initiation).
Number of Participants With Clinically Significant Abnormal Physical Examination Findings
Timeframe: From enrollment to 3-4 weeks after treatment
Change in Body Mass Index (BMI)
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Change in Heart Rate
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Change in Systolic Blood Pressure
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Change in Diastolic Blood Pressure
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Change in Body Temperature
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Number of Participants With Clinically Significant Abnormalities in Clinical Chemistry Parameters
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Number of Participants With Clinically Significant Abnormalities in Hematology Parameters
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).
Number of Participants With Clinically Significant Abnormalities in Urinalysis Parameters
Timeframe: Baseline (Visits 1 and 2) through end of treatment (Visit 4, Week 2).

Arms and interventions

One-week screening - Two week treatment - Follow-upOther

Bile acid + Fatty acid (BAFA)

Drugs: BAFA

Sites

1 site in 1 country

  • Sahlgrenska University HospitalGothenburg, Västra Götaland County, Sweden